Clinical trials: Patients With Diabetes.
COVID19, Diabetes Mellitus
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
The disease caused by SARS-CoV-2, has derived a pandemic in which its evolution and complications depend on the immune capacity of the host.
- Conditions
- COVID19, Diabetes Mellitus, Hypertension, Obesity
- Trial name
- NCT04507867
- Testing
- Nutritional support system (NSS), Conventional nutritional support designed by hospital nutritionists
- Where
- Mexico
- Volunteers
- 80 people
- Sponsor
- Anahuac University
Type 2 Diabetes Mellitus
Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using a Thiazolidinedione or a Thiazolidinedione and Metformin
This study will assess safety and efficacy of exenatide in combination with a thiazolidinedione (TZD) and a TZD plus metformin over 26 weeks in adult patients with type 2 diabetes who have not achieved adequate glycemic control.
- Trial name
- NCT00603239
- Testing
- exenatide
- Where
- 25 sites in United States, Canada and 3 more
- Volunteers
- 165 people
- Sponsor
- AstraZeneca
Hypertension, Stage 2 Hypertension
Study to Evaluate the Efficacy and Safety of the Combination of Valturna and Amlodipine or Valturna and Chlorthalidone Versus Valturna Alone in Patients With Stage 2 Hypertension and Diabetes
This was a study to assess the safety and efficacy of Valturna and amlodipine or Valturna and chlorthalidone when compared to Valturna alone in patients with stage 2 hypertension and diabetes mellitus 2.
- Conditions
- Hypertension, Stage 2 Hypertension, Diabetes
- Trial name
- VALENCIA (NCT01368536)
- Testing
- Valturna, Amlodipine, Chlorthalidone
- Where
- 97 sites in United States, Puerto Rico
- Volunteers
- 975 people
- Sponsor
- Novartis Pharmaceuticals
Ischemic Heart Disease, Ischemic Stroke
Study to Compare 2 Doses of Polycap Versus Single Dose of Polycap With or Without Pottasium
This is a randomized double blind 2x2 factorial controlled trial to evaluate efficacy tolerability of low strength Polycap versus two doses of low strength Polycap in patients with stable cardiovascular disease in reducing blood…
- Conditions
- Ischemic Heart Disease, Ischemic Stroke, Peripheral Vascular Disease, Type 2 Diabetes Mellitus
- Trial name
- TIPSK (NCT01404078)
- Testing
- Single Dose Polycap, Double dose Polycap
- Volunteers
- 518 people
- Sponsor
- St. John's Research Institute
Diabetes Mellitus, Type 2
A Study to Determine the Safety and Efficacy of Albiglutide in Patients With Type 2 Diabetes
A study to determine the safety and efficacy of albiglutide in subjects with type 2 diabetes.
- Trial name
- NCT00838916
- Testing
- albiglutide, insulin glargine
- Where
- 337 sites in United States, Russia and 2 more
- Volunteers
- 779 people
- Sponsor
- GlaxoSmithKline
Type 2 Diabetes Mellitus
Efficacy and Safety Study of MP-513 in Combination With Sulfonylurea in Patients With Type 2 Diabetes
The purpose of this study is to evaluate the safety and efficacy of MP-513 (Teneligliptin) in combination with Sulfonylurea in patients with type 2 Diabetes for 12 weeks administration and to evaluate the safety and efficacy of…
- Trial name
- NCT00974090
- Testing
- Teneli / Teneli + SU
- Where
- Japan
- Volunteers
- 194 people
- Sponsor
- Tanabe Pharma Corporation
Neuropathic Pain
Donepezil Compared to Placebo in Patients With Chronic Neuropathic Pain
Based on laboratory studies, donepezil will improve pain relief more than placebo in patients with chronic neuropathic pain who are currently taking gabapentin or pregabalin.
- Trial name
- NCT01743976
- Testing
- Donepezil
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- Wake Forest University
Type 1 Diabetes
A Study of LY900014 and Insulin Degludec in Participants With Type 1 Diabetes
In this study, participants with type 1 diabetes (T1D) will take the study drug LY900014 and insulin degludec. The reason for this study is to evaluate the amount of time with glucose values within target range.
- Trial name
- NCT04585776
- Testing
- LY900014, Insulin Degludec
- Where
- 3 sites in United States
- Volunteers
- 31 people
- Sponsor
- Eli Lilly and Company
Type 1 Diabetes Mellitus
The PK and PD of Dapagliflozin Therapy in Combination With Insulin in Japanese Subjects With T1DM
This randomized, single-blind, 3 arm, parallel group, placebo controlled PK/PD study will enrol 30 Japanese male and female patients with T1DM and age 18 to 65 years, with inadequate glycemic control on insulin defined as HbA1c ≥…
- Trial name
- NCT02582840
- Testing
- Dapagliflozin 5mg, Dapagliflozin 10mg
- Where
- Japan
- Volunteers
- 42 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
Feasibility Trial Using an Inpatient Insulin Dosing Calculator
The goal of this feasibility trial is to test whether a novel insulin dosing calculator can improve blood glucose management for patients with type 2 diabetes mellitus on hospital admission.
- Trial name
- NCT06206525
- Testing
- Initial insulin dosing calculator
- Where
- 3 sites in United States
- Volunteers
- 38 people
- Sponsor
- University of Washington
Diabetes, Type 2
Study Of Safety And Efficacy Of PF-04991532 In Subjects With Type 2 Diabetes Mellitus
B2611002 is designed to study how safe and effective an investigational medication (PF-04991532) is in people with Type 2 diabetes. Subjects in the study will receive 1 of 5 treatments for 3 months.
- Trial name
- NCT01336738
- Testing
- 150 mg PF-04991532, 450 mg PF-04991532, 750 mg PF-04991532
- Where
- 44 sites in United States, Canada and 5 more
- Volunteers
- 266 people
- Sponsor
- Pfizer
Hypoglycemia, Diabetes Mellitus, Type 1
A Trial to Evaluate the Immunogenicity of Dasiglucagon and GlucaGen in Patients With Type 1 Diabetes Mellitus
The trial's objective is to evaluate the immunogenicity of repeated single doses of dasiglucagon* and GlucaGen following subcutaneous (SC) administration in patients with type 1 diabetes mellitus (T1DM) and further to evaluate…
- Trial name
- NCT03216226
- Testing
- dasiglucagon, GlucaGen
- Where
- 7 sites in United States, Austria and 2 more
- Volunteers
- 112 people
- Sponsor
- Zealand Pharma
Type 2 Diabetes Mellitus
Comparative Study to Evaluate Efficacy and Safety When Metformin Hydrochloride 500 mg Once Daily is Added on to SYR-322 25 mg in Type 2 Diabetic Patients With Inadequate Glycemic Control Despite Treatment With SYR-322 25 mg in Addition to Diet and Exercise Therapy
The purpose of this study was to evaluate the efficacy and safety of 24-week treatment with metformin hydrochloride 500 mg once daily added on to alogliptin (SYR-322) 25 mg in type 2 diabetic patients with inadequate glycemic…
- Trial name
- NCT02068443
- Testing
- Alogliptin, Metformin hydrochloride
- Where
- 27 sites in Japan
- Volunteers
- 374 people
- Sponsor
- Takeda
Type 2 Diabetes Mellitus
MK0431A vs. Pioglitazone in Patients With Type 2 Diabetes Mellitus (0431A-066)
A study to evaluate the efficacy and safety of MK0431A in comparison to a commonly used medication in patients with type 2 diabetes
- Trial name
- NCT00532935
- Testing
- sitagliptin phosphate (+) metformin hydrochloride, Comparator: pioglitazone
- Volunteers
- 517 people
- Sponsor
- Merck Sharp & Dohme LLC
Neuralgia, Postherpetic, Diabetic Neuropathy
Neuropathic Pain Syndrome Patient Study (MK-0000-072)
The purpose of this study is to determine the best way to conduct clinical trials in patients with neuropathic pain (nerve pain). This study will see if generic pregabalin has any effect on neuropathic pain.
- Conditions
- Neuralgia, Postherpetic, Diabetic Neuropathy, Painful Small-Fiber Neuropathy, Idiopathic Distal Sensory Polyneuropathy
- Trial name
- NCT00570310
- Testing
- Comparator: pregabalin
- Volunteers
- 104 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
Comparison of Fasiglifam (TAK-875) With Sitagliptin When Used in Combination With Metformin in Patients With Type 2 Diabetes
The purpose of this study is to evaluate the efficacy of fasiglifam (TAK-875) plus metformin compared with sitagliptin plus metformin on glycemic control over a 24-week Treatment Period.
- Trial name
- NCT01834274
- Testing
- Fasiglifam (TAK-875), Sitagliptin, Metformin
- Where
- 104 sites in United States, Argentina and 11 more
- Volunteers
- 96 people
- Sponsor
- Takeda
Type 2 Diabetes Mellitus
MK0431A Comparative Study in Patients With Type 2 Diabetes (0431A-079)(COMPLETED)
The purpose of this study is to investigate the efficacy and safety of an investigational treatment for type 2 diabetes mellitus.
- Trial name
- NCT00482729
- Testing
- sitagliptin phosphate (+) metformin hydrochloride, metformin
- Volunteers
- 1,246 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
Ascertainment of EMR-based Clinical Covariates Among Patients Receiving Oral and Non-insulin Injected Hypoglycemic Therapy
The objective of this study is to identify EMR-based clinical covariates and quantify their association with the prescribing of each specific type 2 diabetes (T2DM) medication under investigation.
- Trial name
- NCT02140645
- Testing
- linagliptin
- Where
- United States
- Volunteers
- 166,613 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus Type 2
Risk of Nocturnal Hypoglycemia and Arrhythmias With Sitagliptin Versus Glimepiride in Patients With Type 2 Diabetes
This exploratory double blind randomized active controlled study is designed to assess the effects of a treatment with therapeutical dosage of sitagliptin versus therapeutical dosage of glimepiride as add on therapy in patients…
- Trial name
- NCT02373865
- Testing
- Sitagliptin, Glimepiride
- Where
- Germany
- Volunteers
- 4 people
- Sponsor
- GWT-TUD GmbH
Diabetes Mellitus, Type 2
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BI 10773 in Type II Diabetes Patients With Different Degrees of Renal Impairment
Assessment of the effect of normal and impaired kidney function on the pharmacokinetics, pharmacodynamics and safety of BI 10773
- Trial name
- NCT01907113
- Testing
- BI 10773
- Where
- 2 sites in Germany
- Volunteers
- 40 people
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.